Safety of Adjuvant Oral Uracil-Tegafur Therapy in Older Patients With Resected Non-small Cell Lung Cancer
Adjuvant UFT therapy was generally safe in patients aged ≥75 years. Nevertheless, dose adjustments may be necessary in older patients. In a super-aging society, these findings underscore the importance of considering not only chronological age but also each patient's overall condition when making decisions regarding adjuvant UFT therapy.
Authors
- Toshiki Okasaka
- Toshinari Ito (ORCID: https://orcid.org/0009-0000-5005-1568)
- Yuya Iwata
- Yuji Akiba
- Takahiro Ichino
Institutions
- Japanese Red Cross Nagoya Daiichi Hospital (JP)
- Toyota Kosei Hospital (JP)
Publication Details
- Journal
- Cancer Diagnosis & Prognosis
- Published
- 2026-01-03
- DOI
- https://doi.org/10.21873/cdp.10507
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00